/

TCRX

TScan Therapeutics, Inc.Closed

0.2167−0.02 −8.91%USD

NasdaqGM · as of Oct 13, 16:00 ET · 15m delayAfter hours 0.2171 +0.18%

Open

0.2400

Prev close

0.2379

Day range

0.21300.2400

52-week range

0.21302.57

Volume

456.37K0.60×

Mkt cap

14.69M

P/E ttm

—

Fwd P/E

-0.38

EPS ttm

-0.9100

Div yield

0.00%

Earnings

—

From 52w high

−91.57%

Price Chart

Yahoo Finance · delayed

TCRXOct 13, 2026O 0.2400H 0.2400L 0.2120C 0.2170−0.0210 (−8.82%)Vol 461.40K

SMA 500.5062
SMA 2000.9097

1Y change −90.18% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

TCRX TScan Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −21.09%
1 month: −32.19%
3 months: −76.67%
6 months: −79.53%
Year to date: −78.30%
1 year: −90.14%

Valuation & ownership

Market cap: 14.69M
Enterprise value: 5.42M
P/E (ttm): —
Forward P/E: -0.38
PEG ratio: —
Price / book: 0.21
Price / sales (ttm): 2.07
EV / EBITDA: -0.05
EPS (ttm): -0.9100
EPS (forward): -0.5725
Beta (5y monthly): 1.14
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 63.50M
Float: 54.36M
Short % of float: 5.27%
Short ratio (days): 1.91
Held by insiders: 1.76%
Held by institutions: 67.88%
Avg volume (3m): 758.21K
50-day average: 0.5163
200-day average: 0.9138
52-week change: −90.14%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): oversold 21.4
vs 50-day SMA: −57.13%
vs 200-day SMA: −76.15%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 16.21%
Realised vol (20d, ann.): 99.5%
From 52-week high: −91.56%
From 52-week low: +2.36%

ANR

Analyst Consensus

2 analysts

Consensus

Hold

2.60 on a 1 (strong buy) – 5 (sell) scale

Mean target

1.00

+361.47% implied

Low 1.00Median 1.00High 1.00

Recommendation trend

Now1 / 4 / 0
1m ago5 / 1 / 0

DES

About TScan Therapeutics, Inc.

Yahoo Finance profile

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 138
Headquarters: Waltham, MA, United States
Website: tscan.com
Officers: Dr. Gavin MacBeath Ph.D. CEO, Principal Financial Officer, Principal Accounting Officer & Director
Dr. Stephen J. Elledge Ph.D. Co-Founder & Chairman of Scientific Advisory Board
Mr. Tomasz Kula Ph.D.

SEAS

Seasonality · TCRX

2021–2026 · monthly returns

Strongest month Jul +17.81%Weakest month Dec −25.28%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	2.0	3.9	-4.7	14.9	-6.9	-9.3	-24.2	-1.7	-56.8	-31.2			−78.3%
2025	-15.5	-18.3	-34.3	16.3	-10.9	1.4	20.0	3.4	1.1	6.6	-42.8	-9.9	−67.1%
2024	-12.3	32.1	17.6	-2.8	10.8	-31.6	22.1	-21.1	-11.5	-8.8	5.1	-36.3	−47.9%
2023	17.4	62.1	-28.8	8.1	1.3	8.7	-10.4	6.3	7.6	50.4	69.6	-10.7	+276.1%
2022	7.3	-13.0	-33.3	-23.2	48.8	-1.7	39.6	-37.4	10.9	-11.5	-20.0	-28.2	−65.6%
2021								-8.4	-6.2	5.0	-12.6	-41.3	−53.6%

INSD

Insider Activity · TCRX

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Sep 30, 2026	Macbeath GavinChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	1.00M	—
Sep 30, 2026	Zdraveski ZoranOfficer	Stock Award(Grant) at price 0.00 per share.	300K	—
Dec 22, 2025	Lynx1 Capital Management LpBeneficial Owner of more than 10% of a Class of Security	Purchase at price 0.90 per share.	161.8K	$145.53K
May 19, 2025	Lynx1 Capital Management LpBeneficial Owner of more than 10% of a Class of Security	Purchase at price 1.20 per share.	2.59M	$3.11M
Dec 12, 2024	Lynx1 Capital Management LpBeneficial Owner of more than 10% of a Class of Security	Purchase at price 2.90 - 3.01 per share.	131.8K	$385.77K
Nov 14, 2024	Lynx1 Capital Management LpBeneficial Owner of more than 10% of a Class of Security	Purchase at price 4.34 per share.	947	$4.11K

13F

Investors Holding TCRX

latest 13F filings of 29 followed managers

Investors holding TCRX
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$1.3M	0.00%	1.33M	−2.8%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

TCRX

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

TCRX

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About TScan Therapeutics, Inc.

Seasonality · TCRX

Insider Activity · TCRX

Congress Trades · TCRX

Investors Holding TCRX

Investors Holding TCRX

Congress Trades · TCRX

Insider Activity · TCRX

Seasonality · TCRX

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About TScan Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News